Navigation Links
New Drug Aids Muscle Function in Myasthenia Gravis
Date:8/18/2007

Trial of 16 patients saw 46% improvement in symptoms

FRIDAY, Aug. 17 (HealthDay News) -- A new drug -- oral EN101antisense -- reduced the severity of muscle weakness in patients with myasthenia gravis, researchers report.

Myasthenia gravis (MG), which affects about 20 in 100,000 people, causes fatigue and reduced strength in voluntary muscles. Other symptoms may include double vision, drooping eyelids, difficulty swallowing, or slurred speech.

The small open-label study included 16 MG patients who took daily doses of oral EN101antisense for four days and were monitored for a month. On average, the patients experienced a 46 percent reduction in symptom severity. Side effects included dryness of the eyes and mouth.

The study, published in the Aug. 14 issue of Neurology, was supported by the biotechnology company Ester Neuroscience Ltd.

"This is the first time we've been able to show that antisense is effective and safe when taken orally for a neurological disease," study author Dr. Zohar Argov, of the Hadassah Hebrew University Medical Center in Jerusalem, said in a prepared statement.

Further research is planned to study the effects of the drug over a longer period of time.

Antisense is a synthetic, short segment DNA that blocks production of specific proteins. Oral EN101antisense inhibits production of an enzyme called acetylcholine esterase, which plays an important role in the function of the neuromuscular junction, where nerves connect with muscles.

More information

The American Medical Association has more about myasthenia gravis.



-- Robert Preidt



SOURCE: American Academy of Neurology, news release, Aug. 13, 2007


'/>"/>

Copyright©2007 ScoutNews,LLC.

Page: 1

Related medicine news :

1. Mushroom and muscle loss
2. Blood Pressure Drugs maintain muscle strength
3. New treatment for muscle spasms
4. Protein can change worn muscle fibres
5. Stretching the muscles doesnt make them more resilient
6. Protein said to Improve Muscle Loss
7. ‘Protein’ Produced By Overstressed Heart Muscle a Strong Indicator Of Heart Diseae
8. Regeneration of muscle
9. Protein Found To Improve Muscle Loss
10. Strong Pelvic Muscles Found To Facilitate Childbirth
11. Molecule responsible for muscle repair identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... Grocery Company to the list of fine retailers selling biodegradable, hanging flushable wipes ... H.E.B., a large supermarket chain headquartered in San Antonio, Texas, operates more than ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – ... just 19 hours without sleep can compromise motor reaction time, which can increase the risk ... Insurance is sharing the following tips from the NSF to help you sleep better and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... MA (PRWEB) , ... April 28, 2017 , ... People ... for older people. “Wearing a hearing aid doesn’t have the stigma it had when ... & Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... 18, 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), ... Urology, Uro/Gyn and Gynecology markets with innovative and proprietary ... ended March 31, 2017 after the market close on ... will host a conference call and webcast to discuss ... 2, 2017 at 4:30 p.m. Eastern Time (3:30 p.m. ...
Breaking Medicine Technology: